The Paradise uRDN system is currently commercially available for patients in the US having received FDA approval in November 2023. It is indicated to reduce blood pressure as an adjunctive treatment ...

While high blood pressure can contribute to renovascular disease, having renal (kidney) problems can also increase blood ...

Treatment of Liddle syndrome with ... attending physician in the Division of Nephrology and Hypertension, and Professor of Medicine, Mayo Medical School, Rochester, MN, USA. Competing Interests ...

Medically reviewed by Khadeja Haye, MD Postpartum hypertension is high blood pressure that begins after giving birth. Some ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

Treatment of systolic hypertension in the elderly should be based on nonpharmacological measures and medical therapy if the systolic hypertension cannot be controlled by conservative therapy alone.

A groundbreaking development in hypertension treatment has emerged from the University of South Wales, offering new hope for the 1.28 billion adults worldwide affected by high blood pressure.

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...

The consequences of primary aldosteronism mainly result from the activation of the mineralocorticoid receptor. Two of these ...

Blue balls, known medically as epididymal hypertension (EH), can affect ... a more serious health condition that requires medical treatment.